The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Editor’s Choice

Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
Editor's Choice

Targeting the ileo-colonic region: Innovative solutions for sensitive APIs

AUG 21, 2025
EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
Editor's Choice

EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum

JUN 23, 2025
DynaMAP – Precision Metagenomics beyond Sequencing
Editor's Choice

DynaMAP – Precision Metagenomics beyond Sequencing

MAY 27, 2025
The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
Editor's Choice

The Selection of a Pre-Clinical Model is Driven by the Specific Research Question

MAY 13, 2025
Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
Editor's Choice

Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet

APR 3, 2025
Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
Editor's Choice

Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation

MAR 25, 2025
Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
Editor's Choice

Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis

MAR 5, 2025
Scientists decode diet from stool DNA – no questions asked
Editor's Choice

Scientists decode diet from stool DNA – no questions asked

FEB 24, 2025
Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D
Editor's Choice

Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D

NOV 15, 2024